J 2021

The Relation Between Clinical Phenotypes, GOLD Groups/Stages and Mortality in COPD Patients – A Prospective Multicenter Study

BRAT, Kristián, Michal SVOBODA, Jaromir ZATLOUKAL, Marek PLUTINSKÝ, Eva VOLAKOVA et. al.

Základní údaje

Originální název

The Relation Between Clinical Phenotypes, GOLD Groups/Stages and Mortality in COPD Patients – A Prospective Multicenter Study

Autoři

BRAT, Kristián (703 Slovensko, garant, domácí), Michal SVOBODA (203 Česká republika, domácí), Jaromir ZATLOUKAL (203 Česká republika), Marek PLUTINSKÝ (703 Slovensko, domácí), Eva VOLAKOVA (203 Česká republika), Patrice POPELKOVA (203 Česká republika), Barbora NOVOTNA (203 Česká republika), Tomas DVORAK (203 Česká republika) a Vladmir KOBLIZEK (203 Česká republika)

Vydání

International Journal of Chronic Obstructive Pulmonary Disease, Albany, Dove Medical Press, 2021, 1178-2005

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30203 Respiratory systems

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 2.893

Kód RIV

RIV/00216224:14110/21:00121546

Organizační jednotka

Lékařská fakulta

UT WoS

000648310100001

Klíčová slova anglicky

chronic obstructive pulmonary disease; COPD; phenotypes; mortality; cluster; classification and regression tree; CART

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 17. 5. 2022 09:11, Mgr. Tereza Miškechová

Anotace

V originále

Introduction: The concept of phenotyping emerged, reflecting specific clinical, pulmonary and extrapulmonary features of each particular chronic obstructive pulmonary disease (COPD) case. Our aim was to analyze prognostic utility of: “Czech“ COPD phenotypes and their most frequent combinations, ”Spanish” phenotypes and Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages + groups in relation to long-term mortality risk. Methods: Data were extracted from the Czech Multicenter Research Database (CMRD) of COPD. Kaplan-Meier (KM) estimates (at 60 months from inclusion) were used for mortality assessment. Survival rates were calculated for the six elementary “Czech” phenotypes and their most frequent and relevant combinations, “Spanish” phenotypes, GOLD grades and groups. Statistically significant differences were tested by Log Rank test. An analysis of factors underlying mortality risk (the role of confounders) has been assessed with the use of classification and regression tree (CART) analysis. Basic factors showing significant differences between deceased and living patients were entered into the CART model. This showed six different risk groups, the differences in risk were tested by a Log Rank test. Results: The cohort (n=720) was 73.1% men, with a mean age of 66.6 years and mean FEV1 44.4% pred. KM estimates showed bronchiectases/COPD overlap (HR 1.425, p=0.045), frequent exacerbator (HR 1.58, p< 0.001), cachexia (HR 2.262, p< 0.001) and emphysematous (HR 1.786, p=0.015) phenotypes associated with higher mortality risk. Co-presence of multiple phenotypes in a single patient had additive effect on risk; combination of emphysema, cachexia and frequent exacerbations translated into poorest prognosis (HR 3.075; p< 0.001). Of the “Spanish” phenotypes, AE CB and AE non-CB were associated with greater risk of mortality (HR 1.787 and 2.001; both p=0.001). FEV1% pred., cachexia and chronic heart failure in patient history were the major underlying factors determining mortality risk in our cohort. Conclusion: Certain phenotypes (“Czech” or “Spanish”) of COPD are associated with higher risk of death. Co-presence of multiple phenotypes (emphysematous plus cachectic plus frequent exacerbator) in a single individual was associated with amplified risk of mortality.

Návaznosti

15/14/NAP, interní kód MU
Název: Sledování výskytu deficitu alfa 1 antitrypsinu u pacientů s těžkou formou CHOPN
Investor: Ministerstvo zdravotnictví ČR, Sledování výskytu deficitu alfa 1 antitrypsinu u pacientů s těžkou formou CHOPN
5/15/NAP, interní kód MU
Název: Diagnostika bronchogenního karcinomu u nemocných s těžkou formou CHOPN pomocí výpočetní tomografie
Investor: Ministerstvo zdravotnictví ČR, Diagnostika bronchogenního karcinomu u nemocných s těžkou formou CHOPN pomocí výpočetní tomografie